Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

For the quarter ended March 2026, Travere Therapeutics (TVTX) reported revenue of $127.2 million, up 55.6% over the same period last year. EPS came in at -$0.39, compared to -$0.47 in the year-ago ...

Airbnb, Inc. has posted a shareholder letter containing its first quarter 2026 financial results on its Investor Relations website at ...

Affirm Holdings, Inc. ("Affirm" or the "Company") today reported financial results for its fiscal 2026 third quarter ended March 31, 2026. The results, which include a shareholder letter furnished to ...

Travere Therapeutics Inc. (NASDAQ:TVTX) reported first quarter results that fell short of Wall Street expectations, with both earnings and revenue missing analyst ...

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents ...

Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE)-- Ligand Pharmaceuticals ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.